Fintel reports that on January 3, 2025, William Blair initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform recommendation.
Analyst Price Forecast Suggests 109.33% Upside
As of December 23, 2024, the average one-year price target for Denali Therapeutics is $43.62/share. The forecasts range from a low of $28.28 to a high of $94.50. The average price target represents an increase of 109.33% from its latest reported closing price of $20.84 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Denali Therapeutics is 345MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.66.
What is the Fund Sentiment?
There are 514 funds or institutions reporting positions in Denali Therapeutics. This is an increase of 31 owner(s) or 6.42% in the last quarter. Average portfolio weight of all funds dedicated to DNLI is 0.16%, an increase of 8.88%. Total shares owned by institutions increased in the last three months by 9.15% to 149,268K shares. 
The put/call ratio of DNLI is 0.49, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 13,346K shares representing 9.27% ownership of the company. In its prior filing, the firm reported owning 13,764K shares , representing a decrease of 3.13%. The firm increased its portfolio allocation in DNLI by 16.85% over the last quarter.
Wellington Management Group Llp holds 10,727K shares representing 7.45% ownership of the company. In its prior filing, the firm reported owning 9,824K shares , representing an increase of 8.42%. The firm increased its portfolio allocation in DNLI by 34.40% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 8,797K shares representing 6.11% ownership of the company. No change in the last quarter.
Capital Research Global Investors holds 7,909K shares representing 5.50% ownership of the company. In its prior filing, the firm reported owning 7,127K shares , representing an increase of 9.89%. The firm increased its portfolio allocation in DNLI by 31.88% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 5,978K shares representing 4.15% ownership of the company. In its prior filing, the firm reported owning 5,275K shares , representing an increase of 11.76%. The firm increased its portfolio allocation in DNLI by 33.33% over the last quarter.
Denali Therapeutics Background Information
(This description is provided by the company.)
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
